Asunto(s)
Leprostáticos/administración & dosificación , Leprostáticos/normas , Lepra/diagnóstico , Lepra/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Masculino , Pronóstico , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Organización Mundial de la SaludAsunto(s)
Leprostáticos/normas , Lepra/complicaciones , Lepra/terapia , Guías de Práctica Clínica como Asunto , Trastornos Somatosensoriales/etiología , Trastornos Somatosensoriales/terapia , Corticoesteroides/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Femenino , Humanos , Leprostáticos/uso terapéutico , Masculino , Sensibilidad y Especificidad , Índice de Severidad de la EnfermedadRESUMEN
A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy
Asunto(s)
Humanos , Lepra/epidemiología , Lepra/prevención & control , Lepra/tratamiento farmacológico , Recurrencia/prevención & control , Clofazimina/uso terapéutico , Dapsona/uso terapéutico , Leprostáticos/administración & dosificación , Leprostáticos/historia , Leprostáticos/normas , Leprostáticos/uso terapéutico , Rifampin/uso terapéuticoRESUMEN
The recent World Health Organization multicentric field study on the treatment of paucibacillary (PB) leprosy patients with single skin lesion (SSL) and a single dose of rifampin-ofloxacin-minocycline (ROM) brought new hope to those who are engaged in the eradication of leprosy from India. Being encouraged by the WHO report, we undertook the present hospital-based study and found that PB leprosy patients with SSL were morphologically and histopathologically heterogeneous. The histological spectrum of SSL ranged from indeterminate through tuberculoid (TT) to borderline tuberculoid (BT) leprosy, and most patients had active BT leprosy. Ninety new, untreated PB leprosy patients with SSL were included in the present study for comparative assessment of the efficacies of ROM and ROM plus Convit vaccine therapies. Children, pregnant women, lactating mothers and patients with any thickening of nerves were excluded. All patients were bacteriologically negative (skin-smear test) but lepromin reactive. The patients were divided into two groups after proper matching for morphological and histological status of SSL: a) The test group included 60 patients and the control group included 30 patients. The test group was given a single dose of ROM initially and two injections of low-dose Convit vaccine, one initially and the other at the end of 3 months. b) The control group was given only a single dose of ROM initially. Both groups were followed clinically every 2 weeks for 6 months and retested for histological, bacteriological and lepromin status at the end of 6 months. Thereafter, they were followed clinically every month for another 6 months. In the test group, the SSL resolved in 33.3%, regressed in 48.3%, and remained active in 18.3% of the patients, while the granuloma disappeared in 70% of the cases. Only one patient developed neuritis, and in another patient the disease relapsed on the eighth month. On the other hand, the SSL in the control patients resolved, regressed and remained active in 13.3%, 63.3% and 23.3% of the cases, respectively, while the granuloma disappeared in 53.3% of the cases. In the seven patients who remained active, the disease course was progressive, and two of them developed neuritis. The clinical outcome of the patients treated with ROM plus low-dose Convit vaccine was statistically superior to those treated with single-dose ROM therapy alone.
Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Vacunas Bacterianas/uso terapéutico , Leprostáticos/uso terapéutico , Lepra Lepromatosa/tratamiento farmacológico , Minociclina/uso terapéutico , Ofloxacino/uso terapéutico , Rifampin/uso terapéutico , Adyuvantes Inmunológicos/normas , Adyuvantes Inmunológicos/uso terapéutico , Adolescente , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/normas , Antiinfecciosos/administración & dosificación , Antiinfecciosos/normas , Vacunas Bacterianas/normas , Quimioterapia Combinada , Femenino , Humanos , India , Leprostáticos/administración & dosificación , Leprostáticos/normas , Lepra Lepromatosa/inmunología , Lepra Lepromatosa/patología , Masculino , Persona de Mediana Edad , Minociclina/administración & dosificación , Minociclina/normas , Mycobacterium leprae/efectos de los fármacos , Mycobacterium leprae/inmunología , Ofloxacino/administración & dosificación , Ofloxacino/normas , Rifampin/administración & dosificación , Rifampin/normasRESUMEN
This article compiles information on various therapies used in feline dermatology. Information on the following therapeutic agents and devices is discussed: antibiotics, antifungals, antileprosy drugs, antiparasiticides, antivirals, antihistamines, behavior modification drugs, fatty acids, progestogens, steroids, immunomodulating drugs, chemotherapeutic/immunosuppressive agents, retinoids, mechanical devices, hyposensitization, immunotherapy, food elimination trials, hypoallergenic diets, and miscellaneous topical agents such as polyhydroxydine solution, tar, and benzocaine-containing creams.